Reportlinker Adds Small Molecule Kinase Inhibit...(p; Analytics I-3 Product Definitions ...)

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Kinase Inhibitors Industry: A Prelude II-1

Understanding Kinase Inhibitors II-1

Drug Development Interest in Kinase Inhibitors Soars II-1

Table 1: Clinical Phase Transition Percentage for Novel Kinase Inhibitor Compounds in Clinical Development - All Drugs Vs Kinase Inhibitors, During the Period (1995-2007) (includes corresponding Graph/Chart) II-2

Protein Kinases As Potential Drug Targets: Opportunities Abound II-2

Kinase Profiling: The Backbone for pKi Drug Development II-2

Developing Kinase Inhibitors II-3

Kinase Inhibitors: Huge Potential Envisaged in the Treatment of Cancer II-3

Rising Incidences of Cancer & Unmet Treatment Needs: A Prime Driver II-4

Table 2: Global New Cases Registered and Total number of Deaths Resulting From Cancer (2007): Breakdown by Male and Female (In Million) II-4

In the Cancer End-Use Market Growth Fundamentals Get Stronger II-4

Interest in Non-Cancer Therapies Gains TractionII-4

Multi-Targeted Kinase Inhibitors: The Next Frontier II-5

Rising Incidences of Resistance Sparks Interest in Combination Drug Therapies II-5

Single Vs Multi-Target Kinase Inhibitor Drugs II-6

Tough Regulatory Riders Threaten to Slow Down Number of Approvals II-6

Spiraling Cost of Next Generation Cancer Drugs: A Cause for Concern II-7

Table 3: Average Monthly Costs of Anti-Cancer Drugs (2007):

Breakdown of Treatment Costs by Cancer Drug Brands - Rituxan, Erbitux, Revilimid, Avastin - High Dose, Avastin - Low Dose, Nexavar, Sutent, Herceptin, Gleevec, Tarceva, Tykerb, Iressa, Vectibix, Torisel and Targeted Therapies (In US$) for US, EU and Japan II-8

Adequate Reimbursements: Critical to Product Success in the Marketplace II-8

'/>"/>